Resistance Testing Versus Adherence Support for Management of Patients with Virologic Failure on First-Line Antiretroviral Therapy
REVAMP study is an open-label randomized controlled trial being conducted in Uganda and South Africa. It enrolls people living with HIV who have virologic failure on first line antiretroviral therapy and randomizes them to standard of care or immediate HIV resistance testing. The overarching goal of the study is to assess the efficacy, measured by viral resuppression, and cost-effectiveness of adding routine resistance testing to the management first-line treatment failure in sub-Saharan Africa.
Principle Investigators: Dr. Mark Siedner (MGH) and Dr. Bosco Bwana Mwebesa (MUST)